Search

Your search keyword '"DE VITA, Ferdinando"' showing total 779 results
Start Over Author "DE VITA, Ferdinando"
779 results on '"DE VITA, Ferdinando"'

1. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study

Author

Nappo, Floriana, Fornaro, Lorenzo, Pompella, Luca, Catanese, Silvia, Lavacchi, Daniele, Spallanzani, Andrea, Cappetta, Alessandro, Puzzoni, Marco, Murgioni, Sabina, Barsotti, Giulia, Tirino, Giuseppe, Pellino, Antonio, Vivaldi, Caterina, Strippoli, Antonia, Aprile, Giuseppe, Di Donato, Samantha, Mazza, Elena, Prisciandaro, Michele, Antonuzzo, Lorenzo, Zagonel, Vittorina, Cascinu, Stefano, De Vita, Ferdinando, and Lonardi, Sara

Published
2023
Full Text
View/download PDF

4. Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

Author

Pietrantonio, Filippo, primary, Randon, Giovanni, additional, Lonardi, Sara, additional, Garattini, Silvio Ken, additional, Tamberi, Stefano, additional, Giommoni, Elisa, additional, Di Donato, Samantha, additional, Fornaro, Lorenzo, additional, Brunetti, Oronzo, additional, De Vita, Ferdinando, additional, Frassineti, Giovanni Luca, additional, Chini, Claudio, additional, Spallanzani, Andrea, additional, Bethaz, Valerie, additional, Strippoli, Antonia, additional, Latiano, Tiziana Pia, additional, Cardellino, Giovanni Gerardo, additional, Palermo, Federica, additional, Miceli, Rosalba, additional, and Di Bartolomeo, Maria, additional

Published
2024
Full Text
View/download PDF

5. Gastric Cancer: Advanced/Metastatic Disease

Author

De Vita, Ferdinando, Tirino, Giuseppe, Pompella, Luca, Petrillo, Angelica, Riva Sanseverino, Eleonora, Editor-in-Chief, Amenta, Carlo, Series Editor, Carapezza, Marco, Series Editor, Chiodi, Marcello, Series Editor, Laghi, Andrea, Series Editor, Maresca, Bruno, Series Editor, Micale, Giorgio Domenico Maria, Series Editor, Mocciaro Li Destri, Arabella, Series Editor, Öchsner, Andreas, Series Editor, Piva, Mariacristina, Series Editor, Russo, Antonio, Series Editor, Seel, Norbert M., Series Editor, Peeters, Marc, editor, Incorvaia, Lorena, editor, and Rolfo, Christian, editor

Published
2021
Full Text
View/download PDF

6. Cancer of the Esophagus

Author

Fiorentino, Eugenio, Petrillo, Angelica, Pompella, Luca, Macaione, Ina, De Vita, Ferdinando, Riva Sanseverino, Eleonora, Editor-in-Chief, Amenta, Carlo, Series Editor, Carapezza, Marco, Series Editor, Chiodi, Marcello, Series Editor, Laghi, Andrea, Series Editor, Maresca, Bruno, Series Editor, Micale, Giorgio Domenico Maria, Series Editor, Mocciaro Li Destri, Arabella, Series Editor, Öchsner, Andreas, Series Editor, Piva, Mariacristina, Series Editor, Russo, Antonio, Series Editor, Seel, Norbert M., Series Editor, Peeters, Marc, editor, Incorvaia, Lorena, editor, and Rolfo, Christian, editor

Published
2021
Full Text
View/download PDF

8. Pancreatic Neuroendocrine Tumors: What Is the Best Surgical Option?

Author

Patrone, Renato, primary, Mongardini, Federico Maria, additional, Conzo, Alessandra, additional, Cacciatore, Chiara, additional, Cozzolino, Giovanni, additional, Catauro, Antonio, additional, Lanza, Eduardo, additional, Izzo, Francesco, additional, Belli, Andrea, additional, Palaia, Raffaele, additional, Flagiello, Luigi, additional, De Vita, Ferdinando, additional, Docimo, Ludovico, additional, and Conzo, Giovanni, additional

Published
2024
Full Text
View/download PDF

9. Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma

Author

Caputo, Carlo, primary, Falco, Michela, additional, Grimaldi, Anna, additional, Lombardi, Angela, additional, Miceli, Chiara Carmen, additional, Cocule, Mariateresa, additional, Montella, Marco, additional, Pompella, Luca, additional, Tirino, Giuseppe, additional, Campione, Severo, additional, Tammaro, Chiara, additional, Cossu, Antonio, additional, Fenu Pintori, Grazia, additional, Maioli, Margherita, additional, Coradduzza, Donatella, additional, Savarese, Giovanni, additional, Fico, Antonio, additional, Ottaiano, Alessandro, additional, Conzo, Giovanni, additional, Tathode, Madhura S., additional, Ciardiello, Fortunato, additional, Caraglia, Michele, additional, De Vita, Ferdinando, additional, and Misso, Gabriella, additional

Published
2024
Full Text
View/download PDF

10. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment.

Author

Giordano, Guido, Milella, Michele, Landriscina, Matteo, Bergamo, Francesca, Tirino, Giuseppe, Santaniello, Antonio, Zaniboni, Alberto, Vasile, Enrico, De Vita, Ferdinando, Re, Giovanni Lo, Vaccaro, Vanja, Giommoni, Elisa, Natale, Donato, Conca, Raffaele, Santini, Daniele, Maiorino, Luigi, Sanna, Gianni, Ricci, Vincenzo, Iop, Aldo, and Montesarchio, Vincenzo

Subjects
PANCREATIC cancer, CANCER patients, METASTASIS, OVERALL survival, PROGRESSION-free survival, PANCREATIC intraepithelial neoplasia
Abstract

Background: Pancreatic cancer (PC) first‐line therapy often consists of polychemotherapy regimens, but choosing a second‐line therapy after disease progression, especially following first‐line FOLFIRINOX, remains a clinical challenge. This study presents results from a large, multicenter, retrospective analysis of Italian patients with metastatic PC (mPC) treated with Nab‐paclitaxel/Gemcitabine (AG) as second or later line of treatment. Main objective of the study is to identify prognostic factors that could inform treatment decisions. Methods: The study included 160 mPC patients treated with AG in 17 Italian institutions. AG was administered according to labelling dose, until disease progression, unacceptable toxicity or patient refusal. Variations in schedules, dose modifications, supportive measures, and response evaluation were determined by individual clinicians' practice. Results: AG was well‐tolerated and exhibited promising clinical activity. The overall response rate (ORR) and the disease control rate (DCR) were 22.5% and 45.6%, respectively. Median progression‐free survival (PFS) and overall survival (OS) were 3.9 and 6.8 months, respectively. Among the patients who received AG as a second‐line therapy (n = 111, 66.9%), median PFS and OS were 4.2 and 7.4 months, respectively. Notably, in the 76 patients (68%) receiving AG after first‐line FOLFIRINOX, an ORR of 19.7% and a DCR of 46.0% were observed, resulting in a median PFS of 3.5 and median OS of 5.7 months. The study identified specific clinical or laboratory parameters (LDH, NLR, fasting serum glucose, liver metastases, ECOG PS, and first‐line PFS) as independent prognostic factors at multivariate level. These factors were used to create a prognostic nomogram that divided patients into three risk classes, helping to predict second‐line OS and PFS. Conclusions: This study represents the largest real‐world population of mPC patients treated with AG as a second or later line of therapy. It supports the feasibility of this regimen following first‐line FOLFIRINOX, particularly in patients with specific clinical and laboratory characteristics who derived prolonged benefit from first‐line therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Pancreatic Neuroendocrine Tumors: What Is the Best Surgical Option?

Author

Patrone, Renato, Mongardini, Federico Maria, Conzo, Alessandra, Cacciatore, Chiara, Cozzolino, Giovanni, Catauro, Antonio, Lanza, Eduardo, Izzo, Francesco, Belli, Andrea, Palaia, Raffaele, Flagiello, Luigi, De Vita, Ferdinando, Docimo, Ludovico, and Conzo, Giovanni

Subjects
PANCREATECTOMY, NEUROENDOCRINE tumors, PANCREATICODUODENECTOMY, PANCREATIC tumors, PANCREATIC cancer, PANCREATIC fistula, REOPERATION, TREATMENT effectiveness
Abstract

Background: Pancreatic neuroendocrine tumors (pNETs) represent a rare subset of pancreatic cancer. Functional tumors cause hormonal changes and clinical syndromes, while non-functional ones are often diagnosed late. Surgical management needs multidisciplinary planning, involving enucleation, distal pancreatectomy with or without spleen preservation, central pancreatectomy, pancreaticoduodenectomy or total pancreatectomy. Minimally invasive approaches have increased in the last decade compared to the open technique. The aim of this study was to analyze the current diagnostic and surgical trends for pNETs, to identify better interventions and their outcomes. Methods: The study adhered to the PRISMA guidelines, conducting a systematic review of the literature from May 2008 to March 2022 across multiple databases. Several combinations of keywords were used ("NET", "pancreatic", "surgery", "laparoscopic", "minimally invasive", "robotic", "enucleation", "parenchyma sparing") and relevant article references were manually checked. The manuscript quality was evaluated. Results: The study screened 3867 manuscripts and twelve studies were selected, primarily from Italy, the United States, and China. A total of 7767 surgically treated patients were collected from 160 included centers. The mean age was 56.3 y.o. Enucleation (EN) and distal pancreatectomy (DP) were the most commonly performed surgeries and represented 43.4% and 38.6% of the total interventions, respectively. Pancreatic fistulae, postoperative bleeding, re-operation, and follow-up were recorded and analyzed. Conclusions: Enucleation shows better postoperative outcomes and lower mortality rates compared to pancreaticoduodenectomy (PD) or distal pancreatectomy (DP), despite the similar risks of postoperative pancreatic fistulae (POPF). DP is preferred over enucleation for the pancreas body–tail, while laparoscopic enucleation is better for head pNETs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’

Author

De Falco, Vincenzo, Poliero, Luca, Vitiello, Pietro Paolo, Ciardiello, Davide, Vitale, Pasquale, Zanaletti, Nicoletta, Giunta, Emilio Francesco, Terminiello, Marinella, Caputo, Vincenza, Carlino, Francesca, Di Liello, Raimondo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Orditura, Michele, De Vita, Ferdinando, Fasano, Morena, Napolitano, Stefania, Martini, Giulia, Della Corte, Carminia Maria, Franco, Renato, Altucci, Lucia, Ciardiello, Fortunato, and Troiani, Teresa

Published
2020
Full Text
View/download PDF

14. Assessment of the DNA Mismatch Repair System Is Crucial in Colorectal Cancers Necessitating Adjuvant Treatment: A Propensity Score-Matched and Win Ratio Analysis

Author

Lieto, Eva, primary, Cardella, Francesca, additional, Wang, Duolao, additional, Ronchi, Andrea, additional, Del Sorbo, Giovanni, additional, Panarese, Iacopo, additional, Ferraraccio, Francesca, additional, De Vita, Ferdinando, additional, Galizia, Gennaro, additional, and Auricchio, Annamaria, additional

Published
2023
Full Text
View/download PDF

15. Results of the observational prospective RealFLOT study

Author

Giommoni, Elisa, Lavacchi, Daniele, Tirino, Giuseppe, Fornaro, Lorenzo, Iachetta, Francesco, Pozzo, Carmelo, Satolli, Maria Antonietta, Spallanzani, Andrea, Puzzoni, Marco, Stragliotto, Silvia, Sisani, Michele, Formica, Vincenzo, Giovanardi, Filippo, Strippoli, Antonia, Prisciandaro, Michele, Di Donato, Samantha, Pompella, Luca, Pecora, Irene, Romagnani, Alessandra, Fancelli, Sara, Brugia, Marco, Pillozzi, Serena, De Vita, Ferdinando, and Antonuzzo, Lorenzo

Published
2021
Full Text
View/download PDF

16. Correction to: Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study

Author

Marino, Federica Zito, Sabetta, Rosalaura, Pagliuca, Francesca, Brunelli, Matteo, Aquino, Gabriella, Perdonà, Sisto, Botti, Gerardo, Facchini, Gaetano, Fiorentino, Francesco, Di Lauro, Giovanni, De Sio, Marco, De Vita, Ferdinando, Toni, Giorgio, Reis, Rodolfo Borges Dos, Neder, Luciano, and Franco, Renato

Published
2021
Full Text
View/download PDF

17. Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study

Author

Zito Marino, Federica, Sabetta, Rosalaura, Pagliuca, Francesca, Brunelli, Matteo, Aquino, Gabriella, Perdonà, Sisto, Botti, Gerardo, Facchini, Gaetano, Fiorentino, Francesco, Di Lauro, Giovanni, De Sio, Marco, De Vita, Ferdinando, Toni, Giorgio, Borges Dos Reis, Rodolfo, Neder, Luciano, and Franco, Renato

Published
2021
Full Text
View/download PDF

19. Cancer of the Esophagus

Author

Fiorentino, Eugenio, primary, Petrillo, Angelica, additional, Pompella, Luca, additional, Macaione, Ina, additional, and De Vita, Ferdinando, additional

Published
2021
Full Text
View/download PDF

20. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

21. Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer

Author

Napolitano, Stefania, De Falco, Vincenzo, Martini, Giulia, Ciardiello, Davide, Martinelli, Erika, Della Corte, Carminia Maria, Esposito, Lucia, Famiglietti, Vincenzo, Di Liello, Alessandra, Avallone, Antonio, Cardone, Claudia, De Stefano, Alfonso, Montesarchio, Vincenzo, Zampino, Maria Giulia, Bordonaro, Roberto, Scartozzi, Mario, Santini, Daniele, Di Maio, Massimo, De Vita, Ferdinando, Altucci, Lucia, Marrone, Francesca, Ciardiello, Fortunato, Troiani, Teresa, Napolitano, Stefania, De Falco, Vincenzo, Martini, Giulia, Ciardiello, Davide, Martinelli, Erika, Della Corte, Carminia Maria, Esposito, Lucia, Famiglietti, Vincenzo, Di Liello, Alessandra, Avallone, Antonio, Cardone, Claudia, De Stefano, Alfonso, Montesarchio, Vincenzo, Zampino, Maria Giulia, Bordonaro, Roberto, Scartozzi, Mario, Santini, Daniele, Di Maio, Massimo, De Vita, Ferdinando, Altucci, Lucia, Marrone, Francesca, Ciardiello, Fortunato, and Troiani, Teresa

Subjects
Cancer Research, Oncology
Abstract

ImportanceCurrent third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients.ObjectiveTo compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC.Design, Setting, and ParticipantsThis phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from June 2019 to April 2022. Patients with refractory RAS WT MCRC who had a partial or complete response to first-line chemotherapy plus an anti-EGFR monoclonal antibody and an anti-EGFR drug–free interval of 4 or more months during second-line therapy were included.InterventionsPatients were randomized 1:1 to receive panitumumab plus trifluridine-tipiracil or trifluridine-tipiracil alone.Main Outcomes and MeasuresThe primary end point was progression-free survival (PFS). Circulating tumor DNA (ctDNA) extended sequence variation analysis was performed in a subgroup of patients.ResultsOf 62 included patients, 31 received panitumumab plus trifluridine-tipiracil (19 [61.3%] male; median age, 65 years [range, 39-81 years]) and 31 received trifluridine-tipiracil alone (17 [54.8%] male; median age, 66 years [range, 32-82 years]). The primary end point was met. Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) in the trifluridine-tipiracil only (hazard ratio [HR], 0.48; 95% CI, 0.28-0.82; P = .007). Pretreatment plasma RAS/BRAF WT ctDNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine-tipiracil compared with trifluridine-tipiracil, with PFS rates at 6 months of 38.5% vs 13.0% and at 12 months of 15.4% vs 0%. A ctDNA liquid-biopsy extended mutation analysis by FoundationOne Liquid CDx (profiling 324 genes) was performed in a subgroup of patients with baseline plasma RAS/BRAF WT ctDNA; in 15 of 23 patients (65.2%) whose tumors were WT for KRAS, NRAS, BRAFV600E, EGFR, ERBB2, MAP2K1, and PIK3CA, median PFS was 6.4 months (95% CI, 3.7-9.2 months). Within this group of 15 patients, 2 (13.3%) had partial response, 11 (73.3%) had stable disease, and 2 (13.3%) had disease progression as best response.Conclusions and RelevanceIn this RCT, third-line treatment with the anti-EGFR monoclonal antibody panitumumab plus the standard-of-care trifluridine-tipiracil resulted in improved PFS compared with treatment with trifluridine-tipiracil alone among patients with refractory RAS WT MCRC. The findings support the clinical utility of liquid biopsy–guided anti-EGFR rechallenge therapy for refractory RAS WT MCRC.Trial RegistrationClinicalTrials.gov Identifier: NCT05468892

Published
2023

23. Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial

Author

Napolitano, Stefania, primary, Ciardiello, Davide, additional, De Falco, Vincenzo, additional, Martini, Giulia, additional, Martinelli, Erika, additional, Della Corte, Carminia Maria, additional, Esposito, Lucia, additional, Famiglietti, Vincenzo, additional, Di Liello, Alessandra, additional, Avallone, Antonio, additional, Cardone, Claudia, additional, De Stefano, Alfonso, additional, Montesarchio, Vincenzo, additional, Zampino, Maria Giulia, additional, Fazio, Nicola, additional, Di Maio, Massimo, additional, Del Tufo, Sara, additional, De Vita, Ferdinando, additional, Altucci, Lucia, additional, Marrone, Francesca, additional, Ciardiello, Fortunato, additional, and Troiani, Teresa, additional

Published
2023
Full Text
View/download PDF

24. Retraction notice to “Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors” [Lung Cancer 71 (2011) 283–290]

Author

Morgillo, Floriana, primary, D'Aiuto, Elena, additional, Troiani, Teresa, additional, Martinelli, Erika, additional, Cascone, Tina, additional, De Palma, Raffaele, additional, Orditura, Michele, additional, De Vita, Ferdinando, additional, and Ciardiello, Fortunato, additional

Published
2023
Full Text
View/download PDF

25. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

Author

Procaccio, Letizia, primary, Merz, Valeria, additional, Fasano, Morena, additional, Vaccaro, Vanja, additional, Giommoni, Elisa, additional, Pretta, Andrea, additional, Noventa, Silvia, additional, Satolli, Maria Antonietta, additional, Giordano, Guido, additional, Zichi, Clizia, additional, Pinto, Carmine, additional, Zecchetto, Camilla, additional, Barsotti, Giulia, additional, De Vita, Ferdinando, additional, Milella, Michele, additional, Antonuzzo, Lorenzo, additional, Scartozzi, Mario, additional, Zaniboni, Alberto, additional, Spadi, Rosella, additional, Casalino, Simona, additional, Bergamo, Francesca, additional, De Toni, Chiara, additional, Melisi, Davide, additional, and Lonardi, Sara, additional

Published
2023
Full Text
View/download PDF

26. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Author

Vitiello, Pietro Paolo, Cardone, Claudia, Martini, Giulia, Ciardiello, Davide, Belli, Valentina, Matrone, Nunzia, Barra, Giusi, Napolitano, Stefania, Della Corte, Carmina, Turano, Mimmo, Furia, Maria, Troiani, Teresa, Morgillo, Floriana, De Vita, Ferdinando, Ciardiello, Fortunato, and Martinelli, Erika

Published
2019
Full Text
View/download PDF

27. Assessment of the DNA Mismatch Repair System Is Crucial in Colorectal Cancers Necessitating Adjuvant Treatment: A Propensity Score-Matched and Win Ratio Analysis.

Author

Lieto, Eva, Cardella, Francesca, Wang, Duolao, Ronchi, Andrea, Del Sorbo, Giovanni, Panarese, Iacopo, Ferraraccio, Francesca, De Vita, Ferdinando, Galizia, Gennaro, and Auricchio, Annamaria

Subjects
ADJUVANT chemotherapy, PREDICTIVE tests, GENETIC mutation, IMMUNOHISTOCHEMISTRY, COLORECTAL cancer, TUMOR classification, DESCRIPTIVE statistics, DNA repair, POLYMERASE chain reaction, PROGRESSION-free survival, IMMUNOTHERAPY
Abstract

Simple Summary: Around 15% of sporadic colorectal cancers exhibit microsatellite instability. This unique tumor population appears to be poorly responsive to conventional chemotherapy and, conversely, reveals excellent results with immunotherapy. Our data, as demonstrated by propensity score-matched and win ratio analyses, show that there are no substantial differences between unstable and stable tumors in early colorectal cancers treated with surgery alone. On the contrary, stable tumors did much better than unstable tumors in the advanced stages of colorectal cancer undergoing conventional adjuvant treatment. Determination of the status of the DNA mismatch repair system is crucial in high-risk colorectal cancers to optimize treatment. A deficient DNA mismatch repair (MMR) system is identified in a non-negligible part of sporadic colorectal cancers (CRCs), and its prognostic value remains controversial. High tumor mutational burden, along with a poor response to conventional chemotherapy and excellent results from immunotherapy, are the main features of this subset. The aim of this study was to evaluate the predictive value of DNA MMR system status for its best treatment. Four hundred and three CRC patients, operated on from 2014 to 2021 and not treated with immunotherapy, entered this study. Immunohistochemistry and polymerase chain reaction, as appropriate, were used to unequivocally group specimens into microsatellite stable (MSS) and instable (MSI) tumors. The win-ratio approach was utilized to compare composite outcomes. MSI tumors accounted for 12.9% of all series. The right tumor location represented the most important factor related to MSI. The status of the DNA MMR system did not appear to correlate with outcome in early-stage CRCs not requiring adjuvant treatment; in advanced stages undergoing conventional chemotherapy, MSI tumors showed significantly poorer overall and disease-free survival rates and the highest win ratio instead. The determination of DNA MMR status is crucial to recommending correct management. There is clear evidence that instable CRCs needing adjuvant therapy should undergo appropriate treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Author

Di Bartolomeo, Maria, Niger, Monica, Tirino, Giuseppe, Petrillo, Angelica, Berenato, Rosa, Laterza, Maria Maddalena, Pietrantonio, Filippo, Morano, Federica, Antista, Maria, Lonardi, Sara, Fornaro, Lorenzo, Tamberi, Stefano, Giommoni, Elisa, Zaniboni, Alberto, Rimassa, Lorenza, Tomasello, Gianluca, Sava, Teodoro, Spada, Massimiliano, Latiano, Tiziana, Bittoni, Alessandro, Bertolini, Alessandro, Proserpio, Ilaria, Bencardino, Katia Bruna, Graziano, Francesco, Beretta, Giordano, Galdy, Salvatore, Ventriglia, Jole, Scagnoli, Simone, Spallanzani, Andrea, Longarini, Raffaella, and De Vita, Ferdinando

Published
2018
Full Text
View/download PDF

29. Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study

Author

D’Alessandro, Rosalba, primary, Refolo, Maria Grazia, additional, Schirizzi, Annalisa, additional, De Leonardis, Giampiero, additional, Donghia, Rossella, additional, Guerra, Vito, additional, Giannelli, Gianluigi, additional, Lolli, Ivan Roberto, additional, Laterza, Maria Maddalena, additional, De Vita, Ferdinando, additional, Messa, Caterina, additional, and Lotesoriere, Claudio, additional

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Author

Pietrantonio, Filippo, primary, Fucà, Giovanni, primary, Morano, Federica, primary, Gloghini, Annunziata, primary, Corso, Simona, primary, Aprile, Giuseppe, primary, Perrone, Federica, primary, De Vita, Ferdinando, primary, Tamborini, Elena, primary, Tomasello, Gianluca, primary, Gualeni, Ambra Vittoria, primary, Ongaro, Elena, primary, Busico, Adele, primary, Giommoni, Elisa, primary, Volpi, Chiara Costanza, primary, Laterza, Maria Maddalena, primary, Corallo, Salvatore, primary, Prisciandaro, Michele, primary, Antista, Maria, primary, Pellegrinelli, Alessandro, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella M., primary, Pruneri, Giancarlo, primary, de Braud, Filippo, primary, Giordano, Silvia, primary, Cremolini, Chiara, primary, and Di Bartolomeo, Maria, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 1 from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Author

Morgillo, Floriana, primary, Sasso, Ferdinando Carlo, primary, Della Corte, Carminia Maria, primary, Vitagliano, Donata, primary, D'Aiuto, Elena, primary, Troiani, Teresa, primary, Martinelli, Erika, primary, De Vita, Ferdinando, primary, Orditura, Michele, primary, De Palma, Raffaele, primary, and Ciardiello, Fortunato, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Author

Pietrantonio, Filippo, primary, Fucà, Giovanni, primary, Morano, Federica, primary, Gloghini, Annunziata, primary, Corso, Simona, primary, Aprile, Giuseppe, primary, Perrone, Federica, primary, De Vita, Ferdinando, primary, Tamborini, Elena, primary, Tomasello, Gianluca, primary, Gualeni, Ambra Vittoria, primary, Ongaro, Elena, primary, Busico, Adele, primary, Giommoni, Elisa, primary, Volpi, Chiara Costanza, primary, Laterza, Maria Maddalena, primary, Corallo, Salvatore, primary, Prisciandaro, Michele, primary, Antista, Maria, primary, Pellegrinelli, Alessandro, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella M., primary, Pruneri, Giancarlo, primary, de Braud, Filippo, primary, Giordano, Silvia, primary, Cremolini, Chiara, primary, and Di Bartolomeo, Maria, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Author

Pietrantonio, Filippo, primary, Fucà, Giovanni, primary, Morano, Federica, primary, Gloghini, Annunziata, primary, Corso, Simona, primary, Aprile, Giuseppe, primary, Perrone, Federica, primary, De Vita, Ferdinando, primary, Tamborini, Elena, primary, Tomasello, Gianluca, primary, Gualeni, Ambra Vittoria, primary, Ongaro, Elena, primary, Busico, Adele, primary, Giommoni, Elisa, primary, Volpi, Chiara Costanza, primary, Laterza, Maria Maddalena, primary, Corallo, Salvatore, primary, Prisciandaro, Michele, primary, Antista, Maria, primary, Pellegrinelli, Alessandro, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella M., primary, Pruneri, Giancarlo, primary, de Braud, Filippo, primary, Giordano, Silvia, primary, Cremolini, Chiara, primary, and Di Bartolomeo, Maria, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 Legend from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Author

Morgillo, Floriana, primary, Sasso, Ferdinando Carlo, primary, Della Corte, Carminia Maria, primary, Vitagliano, Donata, primary, D'Aiuto, Elena, primary, Troiani, Teresa, primary, Martinelli, Erika, primary, De Vita, Ferdinando, primary, Orditura, Michele, primary, De Palma, Raffaele, primary, and Ciardiello, Fortunato, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 2 Legend from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Author

Morgillo, Floriana, primary, Sasso, Ferdinando Carlo, primary, Della Corte, Carminia Maria, primary, Vitagliano, Donata, primary, D'Aiuto, Elena, primary, Troiani, Teresa, primary, Martinelli, Erika, primary, De Vita, Ferdinando, primary, Orditura, Michele, primary, De Palma, Raffaele, primary, and Ciardiello, Fortunato, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Author

Morgillo, Floriana, primary, Sasso, Ferdinando Carlo, primary, Della Corte, Carminia Maria, primary, Vitagliano, Donata, primary, D'Aiuto, Elena, primary, Troiani, Teresa, primary, Martinelli, Erika, primary, De Vita, Ferdinando, primary, Orditura, Michele, primary, De Palma, Raffaele, primary, and Ciardiello, Fortunato, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Methods from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Author

Pietrantonio, Filippo, primary, Fucà, Giovanni, primary, Morano, Federica, primary, Gloghini, Annunziata, primary, Corso, Simona, primary, Aprile, Giuseppe, primary, Perrone, Federica, primary, De Vita, Ferdinando, primary, Tamborini, Elena, primary, Tomasello, Gianluca, primary, Gualeni, Ambra Vittoria, primary, Ongaro, Elena, primary, Busico, Adele, primary, Giommoni, Elisa, primary, Volpi, Chiara Costanza, primary, Laterza, Maria Maddalena, primary, Corallo, Salvatore, primary, Prisciandaro, Michele, primary, Antista, Maria, primary, Pellegrinelli, Alessandro, primary, Castagnoli, Lorenzo, primary, Pupa, Serenella M., primary, Pruneri, Giancarlo, primary, de Braud, Filippo, primary, Giordano, Silvia, primary, Cremolini, Chiara, primary, and Di Bartolomeo, Maria, primary

Published
2023
Full Text
View/download PDF

38. Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma – A randomized phase II / III trial of the German AIO and Italian GOIM

Author

Goetze, Thorsten O, primary, Hofheinz, Ralf‐Dieter, additional, Gaiser, Timo, additional, Schmalenberg, Harald, additional, Strumberg, Dirk, additional, Goekkurt, Eray, additional, Angermeier, Stefan, additional, Zander, Thomas, additional, Kopp, Hans G, additional, Pink, Daniel, additional, Siegler, Gabriele, additional, Schenk, Michael, additional, De Vita, Ferdinando, additional, Galizia, Gennaro, additional, Maiello, Evaristo, additional, Bechstein, Wolf O, additional, Elshafei, Moustafa, additional, Loose, Maria, additional, Sookthai, Disorn, additional, Brulin, Tanita, additional, Pauligk, Claudia, additional, Homann, Nils, additional, and Al‐Batran, Salah‐Eddin, additional

Published
2023
Full Text
View/download PDF

39. Safety of ramucirumab in patients with advanced gastric cancer in Europe and North America: A prospective observational registry.

Author

Silvestro, Lucrezia, primary, De Vita, Ferdinando, additional, Vogel, Arndt, additional, Ettrich, Thomas Jens, additional, Van Cutsem, Eric, additional, Di Bartolomeo, Maria, additional, D'yachkova, Yulia, additional, Liepa, Astra M., additional, Smolyakova, Natalia, additional, Lukanowski, Mariusz, additional, and Huang, Yu-Jing, additional

Published
2023
Full Text
View/download PDF

42. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

Author

Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, and D’Aniello, Carmine

Published
2019
Full Text
View/download PDF

44. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Author

Di Bartolomeo, Maria, Niger, Monica, Morano, Federica, Corallo, Salvatore, Antista, Maria, Tamberi, Stefano, Lonardi, Sara, Di Donato, Samantha, Berardi, Rossana, Scartozzi, Mario, Cardellino, Giovanni Gerardo, Di Costanzo, Francesco, Rimassa, Lorenza, Luporini, Alberto Gianluigi, Longarini, Raffaella, Zaniboni, Alberto, Bertolini, Alessandro, Tomasello, Gianluca, Pinotti, Graziella, Scagliotti, Giorgio, Tortora, Giampaolo, Bonetti, Andrea, Spallanzani, Andrea, Frassineti, Giovanni Luca, Tassinari, Davide, Giuliani, Francesco, Cinieri, Saverio, Maiello, Evaristo, Verusio, Claudio, Bracarda, Sergio, Catalano, Vincenzo, Basso, Michele, Ciuffreda, Libero, De Vita, Ferdinando, Parra, Hector Soto, Fornaro, Lorenzo, Caporale, Marta, de Braud, Filippo, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

48. Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis

Author

Iovino, Francesco, primary, Diana, Anna, additional, Carlino, Francesca, additional, Ferraraccio, Franca, additional, Antoniol, Giuliano, additional, Fisone, Francesca, additional, Perrone, Alessandra, additional, Zito Marino, Federica, additional, Panarese, Iacopo, additional, Tathode, Madhura S., additional, Caraglia, Michele, additional, Gatta, Gianluca, additional, Ruggiero, Roberto, additional, Parisi, Simona, additional, De Vita, Ferdinando, additional, Ciardiello, Fortunato, additional, Docimo, Ludovico, additional, and Orditura, Michele, additional

Published
2022
Full Text
View/download PDF

50. Trastuzumab Resistance in Breast Cancer

Author

Morgillo, Floriana, Orditura, Michele, Troiani, Teresa, Martinelli, Erika, De Vita, Ferdinando, Ciardiello, Fortunato, Sibilia, Maria, editor, Zielinski, Christoph C., editor, Bartsch, Rupert, editor, and Grunt, Thomas W., editor

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results